Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average) (2016 - 2023)

Historic Shares Outstanding (Weighted Average) for CytomX Therapeutics (CTMX) over the last 10 years, with Q4 2023 value amounting to $73.8 million.

  • CytomX Therapeutics' Shares Outstanding (Weighted Average) rose 1227.32% to $73.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $73.8 million, marking a year-over-year increase of 1227.32%. This contributed to the annual value of $73.8 million for FY2023, which is 1227.32% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Shares Outstanding (Weighted Average) of $73.8 million as of Q4 2023, which was up 1227.32% from $80.7 million recorded in Q3 2023.
  • CytomX Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of $45.1 million in Q1 2019.
  • In the last 5 years, CytomX Therapeutics' Shares Outstanding (Weighted Average) had a median value of $65.1 million in 2021 and averaged $58.6 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Shares Outstanding (Weighted Average) soared by 4125.09% in 2021, and later surged by 67.97% in 2022.
  • Over the past 5 years, CytomX Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $45.3 million in 2019, then increased by 2.79% to $46.6 million in 2020, then soared by 40.12% to $65.3 million in 2021, then rose by 0.68% to $65.7 million in 2022, then grew by 12.27% to $73.8 million in 2023.
  • Its Shares Outstanding (Weighted Average) was $73.8 million in Q4 2023, compared to $80.7 million in Q3 2023 and $66.5 million in Q2 2023.